Reported Friday, Milestone Wins FDA Approval For CARDAMYST, First Self-Administered Nasal Spray For Paroxysmal Supraventricular Tachycardia
Benzinga Newsdesk 10 months ago
News
First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables development
- First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT
- Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm
- FDA approval in PSVT enables development of AFib-RVR under sNDA pathway
- Milestone well-capitalized to launch and commercialize CARDAMYST with existing capital and royalty financing
- Conference call and webcast December 15, 8:00 a.m. ET